# Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine

> **NCT00126984** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 508 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **BIOLOGICAL:** Conjugated meningococcal ACWY-TT (vaccine)
- **BIOLOGICAL:** DTPa/Hib containing vaccine
- **BIOLOGICAL:** Meningitec
- **BIOLOGICAL:** Mencevax ACWY

## Key facts

- **NCT ID:** NCT00126984
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 508 (ACTUAL)
- **Last updated:** 2016-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00126984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00126984, "Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00126984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*